Related Experiment Video
Updated: Jul 19, 2026
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Coronary heart disease risk factors in women
1Association de Cardiologie du Centre, Tours, France.
Insights
Cardiovascular disease is a leading cause of death in women. Hormone replacement therapy after menopause may reduce coronary heart disease risk, but its effectiveness remains debated.
Area of Science:
- Cardiology
- Women's Health
- Endocrinology
Background:
- Cardiovascular disease (CVD) is the leading cause of death in women, accounting for 28% of all deaths.
- Coronary heart disease (CHD) risk increases significantly after menopause, suggesting a protective role for female hormones.
- While aging is a non-modifiable risk factor, modifiable factors like smoking, hypertension, and dyslipidemia are crucial.
Purpose of the Study:
- To investigate the role of female hormones and hormone replacement therapy (HRT) in cardiovascular disease prevention in women.
- To analyze the impact of menopause on cardiovascular risk factors and potential benefits of HRT.
- To address the controversy surrounding HRT's efficacy in preventing CHD and cerebrovascular accidents.
Main Methods:
- Review of existing literature and meta-analyses on CVD in women.
- Analysis of risk factors including age, genetics, lifestyle, and hormonal status.
- Examination of the effects of estrogen and progestogen therapy on cardiovascular outcomes.
Main Results:
- HRT may reduce CHD risk by 25-44% post-menopause, depending on the regimen.
- Menopause leads to decreased HDL cholesterol and increased LDL cholesterol, triglycerides, and blood pressure, elevating CVD risk.
- Despite potential benefits, HRT compliance and its overall role in CVD prevention remain subjects of ongoing research.
Conclusions:
- Menopause marks a critical transition, diminishing natural protection against CHD.
- Early and sustained combined HRT post-menopause is suggested to mitigate CVD risk.
- Further research is needed to optimize HRT strategies and improve patient adherence for cardiovascular health.
Abstract:
Despite the obvious predominance of coronary heart disease in middle-aged men, cardiovascular disease including coronary heart disease and cerebrovascular accidents is currently the major cause of death in women (54% cardiovascular mortality, 46% coronary mortality; 28% of all deaths). Before menopause, coronary heart disease is infrequent which suggests that female hormones and metabolism offer protection. Without hormone replacement therapy after menopause women may develop coronary atherosclerosis. Ageing is among the non-modifiable risk factors for coronary heart disease in women, while genetic predisposition and environmental factors remain controversial. The modifiable risk factors are mostly common to both sexes and include heavy cigarette smoking (especially in women under oral contraception) dyslipidaemia, high blood pressure, and diabetes; some factors are peculiar to women. The delayed onset of coronary heart disease in women, roughly 10 years later than in men, and greater feminine longevity (81 years vs 74 in men on average) points to the potential benefit of post-menopause hormone replacement therapy together with reduction of other modifiable risk factors. After menopause, the protective HDL cholesterol decreases whereas high LDL cholesterol, high triglycerides and high blood pressure are major risk factors for coronary heart disease as well as for cerebrovascular accident. The role of hormone replacement therapy in the prevention of cardiovascular disease in women is still controversial despite the results of meta-analyses which suggest a 25% to 44% reduction in coronary heart disease following oestrogen therapy alone or in combination with progestogen, depending on the hormonal regime. In conclusion, menopause, now considered as the marker for the end of natural protection against coronary heart disease, should be followed by early and prolonged combined hormone replacement therapy in order to reduce the low compliance with long-term hormone replacement therapy.
More Related Videos
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:30Coronary Artery Disease III: Clinical Manifestations
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care